◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ホーム全銘柄 › ELAN · English version

Elanco Animal Health (ELAN)

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街(米国) · 最終更新: 2026-08-16

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.

主要指標

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル(DCF)→

年次損益計算書

損益計算書TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
売上高合計$5.0B$4.7B$4.4B$4.4B$4.4B$4.8B$3.3B$3.1B$3.1B$2.9B$2.9B$2.9B
売上総利益$2.6B$2.0B$1.9B$1.9B$2.0B$2.1B$1.2B$1.4B$1.3B$1.2B$1.3B$1.2B
売上総利益率 %52.6%43.5%43.0%43.9%44.7%43.6%38.1%45.6%42.2%40.6%45.8%41.7%
営業利益(EBIT)$252M$251M$326M$384M$304M($77M)$370M$314M$142M$283M$5M
営業利益率 %5.3%5.7%7.4%8.7%6.4%-2.4%12.0%10.2%4.9%9.7%0.2%
当期純利益($199M)($232M)$338M($1.2B)($78M)($483M)($560M)$68M$86M($311M)($48M)($211M)
純利益率 %-4.0%-4.9%7.6%-27.9%-1.8%-10.1%-17.1%2.2%2.8%-10.8%-1.6%-7.2%
EBITDA$676M$1.5B($224M)$866M$409M$1M$472M$440M$86M$232M($23M)
1株当たり利益(EPS)$-0.41$-0.47$0.68$-2.50$-0.16$-0.99$-1.27$0.18$0.28$-0.87$-0.13$-0.59
発行済株式数(百万株)496M497M492M488M487M441M370M314M356M356M356M

出典: 企業の公開資料(SEC)。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は ELAN のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/ELAN

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.